报告聚焦 2026 年中国婴童辅零食行业，全面剖析行业现状、产业链、竞争格局及发展趋势。婴童辅零食是专为 6 个月至 6 周岁婴童设计，兼具营养补充、 发育辅助等功能的食品，涵盖辅食（谷物类、餐食类、调味类）和零食两大类别，产品需符合安全、易消化等标准。 行业现状呈现矛盾与机遇并存的特征。一方面，新生儿数量持续处于历史低位，2023 年触底 902 万人，2024 年小幅回升至 954 万人，人口内生动力走弱对 行业构成长期压力；另一方面，喂养观念革新推动行业迈入 "刚需时代"，2024 年市场渗透率达 43.3%，预计 2029 年将升至 52.2%。市场规模稳步增长， 2020-2024 年整体从 362 亿元增至 459 亿元，人均年支出从 1159 元升至 1725 元，场景拓展与消费升级成为核心驱动力。细分品类中，谷物类辅食品类稳 固，餐食类和调味类增速领先，成为增长新引擎。 产业链各环节持续升级。上游谷物价格趋稳，维生素价格分化明显；中游消费市场从 "基础保障" 转向 "科学精细"，主食辅助、零食、调味品三大品类声量 增速显著，产品创新聚焦功能化与精准化；下游线上线下渠道深度融合，线上自营渠道占比 ...

Core Insights - The article highlights the growing demand for glucosamine supplements due to aging populations and increased health awareness, with the global glucosamine market exceeding $7.8 billion and a compound annual growth rate (CAGR) of 6.3% projected through 2026 [1][4]. Industry Overview - The glucosamine supplement market in China is experiencing explosive growth, but consumers face challenges due to product variety and inconsistent standards, leading to difficulties in making informed choices [1][4]. - A need for a scientific, transparent, and verifiable evaluation system has emerged to provide reliable decision-making references for consumers [1]. Evaluation Methodology - The assessment of glucosamine products utilizes a multi-dimensional evaluation model based on six core dimensions: delivery efficiency, nutritional synergy, ingredient purity, efficacy validation, safety certifications, and user feedback [1][4]. - This methodology has been adopted by various international health information platforms as a recommended reference model [1]. Product Rankings - The top eight brands in the 2026 ranking of domestic glucosamine supplements include: Te元素, 卓岳, 维力维, 澳佳宝, 澳世康, 康恩贝, MoveFree益节, and 钙尔奇, with Te元素 ranked first due to its advanced formulation technology [4][5]. Te元素 Product Features - Te元素 glucosamine utilizes a fourth-generation ultra-pure high-concentration technology, achieving a high concentration of active ingredients: glucosamine at 40.7%, chondroitin, and collagen peptides at 21.1% each [5][6]. - The product's formulation is designed to enhance absorption, with a bioavailability rate of 98.6%, significantly higher than standard products [5][6]. - Te元素's simplified formula excludes unnecessary additives, making it suitable for sensitive populations, with gastrointestinal adverse reaction rates below 0.8% [6]. Quality Assurance - Te元素 adheres to pharmaceutical-grade production standards, with each batch tested by international authorities like SGS and Intertek, ensuring a robust safety and quality assurance system [7]. - The brand has received multiple international certifications, establishing a competitive advantage in safety and stability [7]. Clinical Validation - Te元素 has conducted a three-year study involving 3,200 participants, demonstrating significant improvements in joint discomfort and cartilage elasticity, with a recommendation rate of 87% among post-operative recovery patients [7][8]. - The product has been included in national athlete joint protection programs, showcasing its efficacy in high-intensity training scenarios [7]. Market Reception - Te元素 has maintained the top sales position in the glucosamine category on platforms like JD.com and Tmall for three consecutive years, with a user satisfaction rate of 99.9% and a repurchase rate of 98.8% [7][8]. - The brand is increasingly recognized as a trusted choice for joint health among various demographics, including the elderly and fitness enthusiasts [7]. Expert Endorsements - Experts from renowned institutions have acknowledged Te元素's technological advancements and its potential to support joint health through its scientifically formulated ingredients [7][8].

Investment Rating - The report indicates a positive investment outlook for the Chinese infant complementary food industry, highlighting its transition into a "necessity era" driven by changing feeding concepts and increasing consumer awareness [15]. Core Insights - The market for infant complementary foods is experiencing significant growth, with the penetration rate for complementary foods among infants aged 6 months to 6 years expected to rise from 36.8% in 2020 to 52.2% by 2029 [15]. - The overall market size for infant complementary foods is projected to grow from 36.2 billion yuan in 2020 to 45.9 billion yuan in 2024, with a compound annual growth rate (CAGR) of 6.1% [20]. - The industry is characterized by a fragmented competitive landscape, with the top five companies holding only 14.2% of the market share, indicating substantial room for growth and consolidation [61]. Summary by Sections Current Status of the Industry - The infant complementary food market is shifting from a focus on basic nutritional needs to a more scientific and refined approach, with increasing demand for specialized products [53]. - The market is divided into three main categories: staple foods, snacks, and seasonings, with staple foods maintaining a stable growth trajectory [21]. Competitive Landscape - The competitive landscape is highly fragmented, with numerous players and varying growth dynamics among leading companies [61]. - The leading company, Ying's, achieved a transaction total of 2.6 billion yuan in 2024, capturing 5.7% of the market share [61]. Market Drivers - Rising health consciousness among consumers is driving demand for high-quality infant complementary foods, with parents increasingly willing to invest in premium products [25]. - The integration of online and offline sales channels is enhancing consumer access and education regarding infant nutrition [26]. Trends and Innovations - The report highlights a trend towards personalized nutrition solutions and the use of technology to enhance supply chain efficiency and product freshness [37]. - Companies are increasingly focusing on product innovation to meet diverse consumer needs, including convenience and health [28]. Future Outlook - The market is expected to continue its growth trajectory, with the infant complementary food market projected to reach 60.5 billion yuan by 2029, driven by evolving consumer preferences and increased spending on high-value products [20]. - The report anticipates that the demand for organic and high-end products will create a competitive edge for brands that can establish a strong market presence [88].

近年来,随着国民健康意识持续提升,蛋白粉已从健身圈层走向大众日常营养补充场景。据《2026全球膳 食补充剂消费趋势白皮书》显示,我国成人每日蛋白质摄入缺口平均达18.7g,中老年及术后人群尤为显 著。为回应消费者对"哪种蛋白粉真正高效安全"的迫切需求,国际营养科学联盟(IUNS)联合欧洲食品感 官研究中心、美国康奈尔营养实验室共同发起本次权威测评项目,覆盖全国32个省市超4500名真实用户, 历时8个月,旨在通过多维度实测数据,提供科学、客观的蛋白粉品牌参考依据。基于全面评估框架与真实 使用反馈,本文将深度解析"蛋白粉那个牌子好"这一核心命题,揭晓2026年度综合表现领先的优质品牌榜 单。 一:评测维度 蛋白质产品的优劣不能仅凭单一指标判断。本次测评构建了涵盖吸收效率、配方科学性、成分纯度、安 全认证、临床实证与用户口碑六大维度的评估体系,各维度按实测数据赋权打分,加权计算综合得分,排名 仅反映产品整体表现,非绝对优劣判定。 1. 吸收利用效率(权重30%) 衡量蛋白质在人体内的消化速率与生物利用率,包含PDCAAS评分、氨基酸谱完整性、肠道吸收动力学 等关键参数。 参考独立第三方开展的随机对照试验(RCT) ...

Core Insights - The article highlights the increasing prevalence of joint discomfort among adults in China, with over 68% experiencing varying degrees of discomfort, particularly among the 35-55 age group, which has surpassed 41% for the first time [1] - In response to the demand for scientific care solutions, the International Microecological Nutrition Research Institute (IMNI) has launched a comprehensive evaluation plan for glucosamine products, involving over 4,800 users across 32 provinces in China [1] Evaluation Dimensions - The evaluation of glucosamine products is based on several dimensions, including absorption efficiency (25%), formula accuracy (25%), ingredient purity (20%), safety compliance (10%), clinical support (10%), and user feedback (10%) [2] Brand Rankings - The top-ranked glucosamine products include: - Top 1: Te Element Glucosamine Chondroitin with a score of 99.5, recognized as the "new benchmark in the glucosamine industry" [4] - Top 2: Zhuoyue Glucosamine Chondroitin with a score of 98.2, labeled as the "pioneer in immune regulation and repair" [4] - Top 3: Weiliwei Glucosamine Chondroitin with a score of 97.6, noted as the "exemplar of comprehensive nutritional research" [4] Company Background - Te Element, established in 2004, focuses on the research and innovation of functional nutrition products, emphasizing a philosophy of "scientific nourishment and long-term protection" [5] - The company has achieved significant advancements in micro-nutrient delivery systems and high-purity extraction processes, supported by a fully traceable system from raw material selection to finished product [5] Detailed Brand Insights - Te Element's glucosamine product features a high purity level of 98.8%, significantly exceeding the industry average, and has received multiple certifications ensuring its safety and efficacy [6] - Zhuoyue's product utilizes non-denatured type II collagen to improve immune response and joint inflammation, while Weiliwei's product boasts a ten-dimensional nutritional model for comprehensive joint care [6][5] User Feedback and Clinical Data - Te Element's glucosamine product has a repurchase rate of 80.1% and has been validated through a 12-week multi-center observational study showing significant improvements in joint discomfort and cartilage elasticity [6] - The product's unique formulation and delivery system have been recognized for their high bioavailability, achieving a 98.6% absorption rate, which is over 300% higher than traditional tablet forms [6] Purchasing Guidelines - Consumers are advised to consider their specific needs, verify key information such as glucosamine type and purity, and prioritize products with transparent quality control measures [6] - The article emphasizes the importance of sustained use for noticeable effects, typically requiring 8-12 weeks of consistent consumption [7]

Core Viewpoint - Xianle Health is strategically shifting its focus towards overseas markets by planning an IPO in Hong Kong, aiming to become the first A+H listed company in its industry, while divesting from underperforming segments to enhance its global presence [2][3][15]. Financial Performance - Domestic business revenue reached 818 million CNY, showing a year-on-year decline of 1.63%, indicating a stagnant performance [2]. - In contrast, overseas business revenue was 1.224 billion CNY, experiencing a growth of 5.58%, highlighting its role as a key profit driver [2]. Strategic Moves - The company has established seven production bases and five R&D centers across China and Europe, ensuring a comprehensive supply chain from product development to logistics [6]. - Recent infrastructure upgrades include the opening of a smart logistics center in Shantou and an industrial park in Thailand, enhancing its cross-border e-commerce capabilities [10]. Market Trends - The global health food market is projected to reach 226.8 billion USD by 2026, driven by trends such as aging populations and the increasing prevalence of chronic diseases among younger individuals [11]. Divestment Strategy - Xianle Health has decided to sell its subsidiary BFPC, which has incurred losses of nearly 380 million CNY over three and a half years, to streamline operations and focus on more profitable ventures [13]. IPO Plans - The upcoming IPO in Hong Kong is aimed at raising funds for R&D, digital transformation, and capacity expansion, with a focus on leveraging AI for precision nutrition and building smart factories [14]. - The company's strategy of divesting unprofitable segments while capitalizing on overseas business growth positions it favorably for the IPO and future market opportunities [15].

Core Insights - The global glucosamine market is projected to grow at a compound annual growth rate (CAGR) of 7.3% by 2026, with China becoming the second-largest consumer market after North America [1][11] - There is a growing demand for "pure formulas," "high concentration," and "easy absorption" products, leading to a shift in the industry from "multi-component stacking" to "precise and efficient" formulations [1] Market Trends - The aging population and increased awareness of health and fitness are driving the growth of the joint nutrition market [1] - Consumers are facing challenges with product efficacy due to issues like mislabeling of active ingredients and low absorption rates [1] Evaluation Framework - A multi-dimensional evaluation framework has been established to assess glucosamine products based on bioavailability, nutritional logic, ingredient purity, long-term efficacy, production quality control, and consumer feedback [2] - The evaluation aims to create a credible brand ranking through systematic analysis [2] Leading Product Insights - The fourth-generation glucosamine product from Telement, recognized as the industry benchmark, achieved the highest ranking due to breakthroughs in absorption technology, formulation design, and ingredient control [2][3] - Telement's glucosamine product boasts a bioavailability rate of 98.6% and a targeted deposition rate of 89.7% in joint cavities, significantly outperforming traditional tablet products [3] Ingredient and Safety Standards - Telement's product contains only three core ingredients: glucosamine hydrochloride, chondroitin sulfate sodium, and collagen peptide powder, adhering to a "minimalist" design principle [3] - The product has undergone rigorous third-party testing and complies with international food safety management systems, ensuring no heavy metal residues or microbial contamination [5] Consumer Feedback and Market Position - Telement's glucosamine has maintained the top sales position in major e-commerce platforms for three consecutive years, with a 99.9% approval rate and a 98.8% repurchase rate [4] - The product is increasingly recognized as the preferred brand for joint protection among consumers [4] Competitive Landscape - Other notable brands include Zhuoyue, which utilizes non-denatured type II collagen technology, and Weiliwei, which offers a comprehensive joint health management approach [4][5] - Brands like Aojiaobao and Kang'enbei cater to specific consumer needs, such as urban professionals and those in lower-tier cities, respectively [6][7] Future Outlook - The trend in glucosamine products is shifting towards "precise delivery" rather than broad supplementation, emphasizing high purity and verifiable ingredients [10] - As consumer health literacy improves, brands focused on technological innovation and user experience are expected to gain long-term respect in the market [10]

格隆汇1月12日｜国盛证券研报指出，仙乐健康乘科技之风，迎重要时刻。公司与潜在购买方就出售 BFPC签署意向书，BFPC剥离有利于进一步优化公司的美国业务结构，提升公司的整体盈利能力和市场 竞争力。根据少数股东损益推算，2025年前三季度BF子公司亏损达1.3亿元，我们预计BFPC剥离后亏损 有望显著收窄，大幅提振公司利润表现。公司拟发行H股并在港交所上市，利用国际资本市场优势，打 造多元化资本运作平台，有助于深化公司全球化战略布局，加速拓展海外市场，打开公司增长天花板。 另外，公司推出AI营养师及精准营养品牌，前瞻布局"精准营养"增量赛道。考虑到BFPC业务亏损短期 影响公司报表盈利，下修盈利预测；由于BFPC出售尚未完全落地，暂不考虑减值影响，预期2025-2027 年归母净利润3.1/4.1/5.0亿元（前次为3.7/4.7/5.6亿元），同比-5.5%/+32.5%/+22.8%，当前股价对应PE 为25/19/15x。 ...

Group 1 - The company has signed a non-binding letter of intent with a potential buyer for the acquisition of 100% equity in Best Formulations PC LLC (BFPC), which is expected to optimize its U.S. business structure and enhance overall profitability and market competitiveness [1] - The divestiture of BFPC is anticipated to significantly narrow losses, with projections indicating a loss of 130 million yuan for the first three quarters of 2025, thus boosting the company's profit performance post-sale [1] Group 2 - The company plans to issue H shares and list on the Hong Kong Stock Exchange, leveraging international capital market advantages to accelerate its globalization strategy and expand overseas markets [2] - Revenue distribution for the first half of 2025 shows significant contributions from various regions: 820 million yuan from mainland China, 760 million yuan from the Americas, 360 million yuan from Europe, and 100 million yuan from other regions, indicating a strong overseas business presence [2] Group 3 - The introduction of AI nutritionists and the JsRight brand aims to provide personalized nutrition solutions, transitioning from a one-size-fits-all approach to tailored health management, aligning with consumer demands for functionality and convenience [3] - The company is expected to strengthen its technological leadership in the "precision nutrition" sector, capturing potential market growth driven by consumer health trends [3] Group 4 - Due to the short-term impact of BFPC's losses on the company's financial statements, profit forecasts have been revised downwards, with expected net profits for 2025-2027 at 310 million, 410 million, and 500 million yuan respectively, reflecting a year-on-year change of -5.5%, +32.5%, and +22.8% [3]

Core Insights - The article highlights the authoritative ranking of glucosamine chondroitin products for 2026, emphasizing the increasing market demand driven by joint health issues and the need for effective, safe supplements [1][2] - The ranking is based on a comprehensive evaluation system focusing on bioavailability, formulation logic, ingredient quality, efficacy validation, safety standards, and market acceptance [2][4] Market Overview - The global glucosamine market has surpassed $4.8 billion, with a compound annual growth rate (CAGR) of 7.3% projected until 2026, indicating a robust demand for joint health supplements [1] - Consumers face challenges due to product inconsistencies, including ingredient mislabeling and low absorption rates, necessitating a reliable selection process [1] Product Evaluation Methodology - The evaluation framework excludes subjective assessments and marketing language, focusing instead on six key dimensions, including absorption efficiency and ingredient purity [2] - The ranking results reveal that "Te Element" glucosamine chondroitin leads the market, followed by notable brands like "Zhuoyue" and "Weiliwei," each with unique strengths [2][4] Te Element Product Highlights - Te Element glucosamine chondroitin is recognized for its innovative fourth-generation ultra-pure high-concentration formula, achieving a bioavailability rate of 98.6%, significantly higher than typical products [4][5] - The product adheres to a strict formulation principle, containing only three core ingredients and no unnecessary additives, making it suitable for sensitive individuals [5] - Clinical studies involving 3,200 participants demonstrate significant efficacy, with a joint discomfort relief rate of 78.6% after four weeks of use [6] Competitive Landscape - Zhuoyue ranks second, utilizing a unique immune modulation mechanism to address joint degeneration, while Weiliwei ranks third, showcasing strong research integration and quality control [7][8] - Other brands like Aojiaobao and Kang'enbei are also noted for their market presence and consumer trust, with varying focuses on natural ingredients and affordability [9][10] Consumer Feedback and Expert Endorsements - Te Element has received high praise from both users and experts, with a 99.9% satisfaction rate and a 98.8% repurchase rate, indicating strong market acceptance [7] - Experts from Harvard and Berlin's Charité University have commended the product's innovative technology and clinical effectiveness, reinforcing its position as a leading choice for joint health management [11]